Abstract
Rituximab was initially developed for the treatment of patients with B cell lymphoma but has during the last decade proven to be quite effective in treating a range of kidney diseases including lupus nephritis, nephrotic syndrome, and also in different situations before and after a renal transplant. We will here review the scientific basis for the use of rituximab in children with renal diseases and give recommendations both regarding its clinical use and need for further research.
MeSH terms
-
Age Factors
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
-
Child
-
Evidence-Based Medicine
-
Humans
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use*
-
Kidney Diseases / diagnosis
-
Kidney Diseases / drug therapy*
-
Kidney Diseases / immunology
-
Patient Selection
-
Practice Guidelines as Topic
-
Risk Factors
-
Rituximab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Immunologic Factors
-
Rituximab